文献
J-GLOBAL ID:201702243742152350
整理番号:17A1831618
Peficitinib,経口投与した,1日1回JAK阻害剤の薬物動力学に対するP糖蛋白質阻害剤,ベラパミルの効果【Powered by NICT】
The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor
著者 (7件):
Zhu Tong
(Astellas Pharma Global Development Inc., Northbrook, IL, USA)
,
Howieson Corrie
(Astellas Pharma Global Development Inc., Northbrook, IL, USA)
,
Wojtkowski Tomasz
(Astellas Pharma Global Development Inc., Northbrook, IL, USA)
,
Garg Jay P.
(Astellas Pharma Global Development Inc., Northbrook, IL, USA)
,
Han David
(California Clinical Trials, PAREXEL International, Glendale, CA, USA)
,
Fisniku Ogert
(Astellas Research Institute of America LLC, Skokie, IL, USA)
,
Keirns James
(Astellas Pharma Global Development Inc., Northbrook, IL, USA)
資料名:
Clinical Pharmacology in Drug Development
(Clinical Pharmacology in Drug Development)
巻:
6
号:
6
ページ:
548-555
発行年:
2017年
JST資料番号:
W2780A
ISSN:
2160-7648
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)